Ketryx, a company specializing in agentic continuous compliance platforms for safety-critical product development, announced on June 25, 2026, that William A. Hawkins, former Chairman and CEO of Medtronic, has joined its Board of Directors. Hawkins also participated in the company's Series B financing, signaling strong industry confidence in Ketryx's mission to solve the AI bottleneck in life sciences.
Ketryx focuses on helping companies in safety-critical industries—including medical devices, pharmaceuticals, and robotics—accelerate product development. The platform automatically generates compliant documentation, maintains continuous traceability, and enables safe and verifiable AI at scale within the tools teams already use. According to Ketryx, its AI Agents can reduce manual work by up to 90 percent, helping teams identify and close compliance gaps while improving both speed and quality across the product lifecycle.
Hawkins brings extensive experience from his tenure at Medtronic, where he served as Chairman and CEO. His leadership is expected to guide Ketryx as it expands its reach among top medical device manufacturers. The company is already trusted by four of the world's top five medical device manufacturers, a testament to its ability to transform product lifecycle processes without disrupting existing workflows.
The move comes as the life sciences industry faces increasing pressure to integrate AI while navigating stringent regulatory requirements. Ketryx's platform overlays existing tools to automate documentation and create traceability, addressing a critical bottleneck in the adoption of AI for safety-critical applications. By automating compliance processes, Ketryx aims to help companies release products faster and more safely.
For more information about Ketryx and its platform, visit www.ketryx.com. The full announcement, including downloadable images and bios, is available here.
